These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 9237183)
1. Anti-MOC-31: a potential addition to the pulmonary adenocarcinoma versus mesothelioma immunohistochemistry panel. Sosolik RC; McGaughy VR; De Young BR Mod Pathol; 1997 Jul; 10(7):716-9. PubMed ID: 9237183 [TBL] [Abstract][Full Text] [Related]
2. Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12. Lee I; Radosevich JA; Chejfec G; Ma YX; Warren WH; Rosen ST; Gould VE Am J Pathol; 1986 Jun; 123(3):497-507. PubMed ID: 3717302 [TBL] [Abstract][Full Text] [Related]
3. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma. Ordóñez NG Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877 [TBL] [Abstract][Full Text] [Related]
4. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Comin CE; Novelli L; Boddi V; Paglierani M; Dini S Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372 [TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibody MOC-31 reactivity as a marker for adenocarcinoma in cytologic preparations. Hecht JL; Pinkus JL; Pinkus GS Cancer; 2006 Feb; 108(1):56-9. PubMed ID: 16329115 [TBL] [Abstract][Full Text] [Related]
6. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Ordóñez NG Mod Pathol; 1998 Oct; 11(10):929-33. PubMed ID: 9796717 [TBL] [Abstract][Full Text] [Related]
7. [Immunohistochemistry in the differential diagnosis of mesothelioma and adenocarcinoma. Evaluation of 5 new antibodies and 6 traditional antibodies]. Chenard-Neu MP; Kabou A; Mechine A; Brolly F; Orion B; Bellocq JP Ann Pathol; 1998 Dec; 18(6):460-5. PubMed ID: 10051912 [TBL] [Abstract][Full Text] [Related]
8. The value of thyroid transcription factor-1 in cytologic preparations as a marker for metastatic adenocarcinoma of lung origin. Hecht JL; Pinkus JL; Weinstein LJ; Pinkus GS Am J Clin Pathol; 2001 Oct; 116(4):483-8. PubMed ID: 11601132 [TBL] [Abstract][Full Text] [Related]
9. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions. Friedman MT; Gentile P; Tarectecan A; Fuchs A Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609 [TBL] [Abstract][Full Text] [Related]
11. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. Ordóñez NG Hum Pathol; 1998 Feb; 29(2):166-9. PubMed ID: 9490276 [TBL] [Abstract][Full Text] [Related]
12. Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations? Deniz H; Kibar Y; Güldür ME; Bakir K Pathol Res Pract; 2009; 205(11):749-52. PubMed ID: 19573998 [TBL] [Abstract][Full Text] [Related]
13. E-cadherin, E-selectin and vascular cell adhesion molecule: immunohistochemical markers for differentiation between mesothelioma and metastatic pulmonary adenocarcinoma? Müller AM; Weichert A; Müller KM Virchows Arch; 2002 Jul; 441(1):41-6. PubMed ID: 12111199 [TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis. Carella R; Deleonardi G; D'Errico A; Salerno A; Egarter-Vigl E; Seebacher C; Donazzan G; Grigioni WF Am J Surg Pathol; 2001 Jan; 25(1):43-50. PubMed ID: 11145250 [TBL] [Abstract][Full Text] [Related]
15. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma. Oates J; Edwards C Histopathology; 2000 Apr; 36(4):341-7. PubMed ID: 10759948 [TBL] [Abstract][Full Text] [Related]
16. OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin fixed and paraffin wax embedded material. Edwards C; Oates J J Clin Pathol; 1995 Jul; 48(7):626-30. PubMed ID: 7560168 [TBL] [Abstract][Full Text] [Related]
17. Differential diagnosis between mesotheliomas and metastatic adenocarcinomas using monoclonal antibodies against gastrointestinal carcinoma antigen and stage-specific embryonic antigen. Ernst CS; Atkinson B; Chianese D; Peters J; Perry M; Herlyn M; Koprowski H Appl Pathol; 1986; 4(3):115-24. PubMed ID: 2885017 [TBL] [Abstract][Full Text] [Related]
18. Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases. Chu PG; Weiss LM Mod Pathol; 2002 Jan; 15(1):6-10. PubMed ID: 11796835 [TBL] [Abstract][Full Text] [Related]
19. The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies. Ordóñez NG Am J Surg Pathol; 1997 Dec; 21(12):1399-408. PubMed ID: 9414183 [TBL] [Abstract][Full Text] [Related]
20. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement. Saad RS; Lindner JL; Lin X; Liu YL; Silverman JF Diagn Cytopathol; 2006 Dec; 34(12):801-6. PubMed ID: 17115439 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]